COL.AU

19.09

+0.9%↑

CAR.AU

36.83

+0.55%↑

WOR.AU

14.68

-1.81%↓

RSG.AU

0.73

+1.39%↑

MMS.AU

15.06

+0.67%↑

COL.AU

19.09

+0.9%↑

CAR.AU

36.83

+0.55%↑

WOR.AU

14.68

-1.81%↓

RSG.AU

0.73

+1.39%↑

MMS.AU

15.06

+0.67%↑

COL.AU

19.09

+0.9%↑

CAR.AU

36.83

+0.55%↑

WOR.AU

14.68

-1.81%↓

RSG.AU

0.73

+1.39%↑

MMS.AU

15.06

+0.67%↑

COL.AU

19.09

+0.9%↑

CAR.AU

36.83

+0.55%↑

WOR.AU

14.68

-1.81%↓

RSG.AU

0.73

+1.39%↑

MMS.AU

15.06

+0.67%↑

COL.AU

19.09

+0.9%↑

CAR.AU

36.83

+0.55%↑

WOR.AU

14.68

-1.81%↓

RSG.AU

0.73

+1.39%↑

MMS.AU

15.06

+0.67%↑

Home・Listă Acțiuni・CSL Ltd

CSL Ltd

Închisă

Sector

297.17 -0.85

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

296.95

Maxim

300.52

Indicatori cheie
By Trading Economics
Venit	1.9B
Vânzări	8.1B
EPS	4.159
Marjă de profit	23.606

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+8.03 upside

Statistici piață
By TradingEconomics
Capitalizare de piață	-686M 148B
Deschiderea anterioară	298.02
Închiderea anterioară	297.17

Sentimentul știrilor

By Acuity

76%

24%

342 / 383 Clasament în Industrials

CSL Ltd Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 aug. 2024, 23:23 UTC

Câștiguri

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

12 aug. 2024, 22:49 UTC

Câștiguri

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

12 feb. 2024, 22:16 UTC

Câștiguri

CSL Says 1st Half Profit Rises, Boosts Dividend -- Update

12 feb. 2024, 22:00 UTC

Câștiguri

CSL Says 1st Half Profit Rises, Boosts Dividend

13 aug. 2024, 00:33 UTC

Market Talk

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

12 aug. 2024, 22:34 UTC

Câștiguri

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

12 aug. 2024, 22:18 UTC

Câștiguri

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

12 aug. 2024, 22:18 UTC

Câștiguri

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

12 aug. 2024, 22:17 UTC

Câștiguri

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

12 aug. 2024, 22:16 UTC

Câștiguri

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

12 aug. 2024, 22:15 UTC

Câștiguri

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

12 aug. 2024, 22:14 UTC

Câștiguri

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

12 aug. 2024, 22:13 UTC

Câștiguri

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

12 aug. 2024, 22:13 UTC

Câștiguri

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

12 aug. 2024, 22:11 UTC

Câștiguri

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

12 aug. 2024, 22:10 UTC

Câștiguri

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

12 aug. 2024, 22:09 UTC

Câștiguri

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

12 aug. 2024, 22:08 UTC

Câștiguri

CSL FY Underlying Profit US$2.91 Billion, Up 11% On-Year

12 aug. 2024, 22:07 UTC

Câștiguri

CSL FY Net Profit US$2.64 Billion, Up 20% On-Year

12 aug. 2024, 22:07 UTC

Câștiguri

CSL Final Dividend US$1.45/Share

13 feb. 2024, 01:50 UTC

Market Talk

Câștiguri

CSL Still Confident on Long-Term Value at Vifor Business -- Market Talk

13 feb. 2024, 00:39 UTC

Market Talk

Câștiguri

UBS Sees Mixed Bag in CSL's Half-Year Results -- Market Talk

12 feb. 2024, 22:01 UTC

Câștiguri

CSL Says 1H Profit Rises, Boosts Dividend -- Update

12 feb. 2024, 21:45 UTC

Top știri

Câștiguri

CSL Says 1H Profit Rises, Boosts Dividend

12 feb. 2024, 21:35 UTC

Câștiguri

CSL Says 1H Result Driven by CSL Behring Unit, Especially Immunoglobulins

12 feb. 2024, 21:33 UTC

Câștiguri

CSL Anticipates Loss in 2H for Flu-Vaccine Unit Seqirus Due to Seasonality of Business

12 feb. 2024, 21:33 UTC

Câștiguri

CSL Says FY 2024 Underlying Profit Growth Expected 13%-17% on-Year

12 feb. 2024, 21:32 UTC

Câștiguri

CSL Says Underlying Profit Expected in Range of US$2.9-US$3.0 Bln at Constant Currency

12 feb. 2024, 21:31 UTC

Câștiguri

CSL Reaffirms Previous Guidance

12 feb. 2024, 21:30 UTC

Câștiguri

CSL 1H Underlying Profit Up 13% on Constant Currency Basis

Comparație

Modificare preț

CSL Ltd Așteptări

Obiectiv de preț

By TipRanks

8.03% sus

Prognoză pe 12 luni

Medie 324.385 AUD 8.03%

Maxim 352 AUD

Minim 278 AUD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCSL Ltd - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

11 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 11 analiști care au acordat evaluări ale acțiunilor CSL Ltd - Dist în ultimele 3 luni.

Sentiment

By Acuity

342 / 383 Clasament în

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre CSL Ltd

CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.